肿瘤突变负荷作为乳腺癌免疫治疗的新兴生物标志物的研究进展

doi:10.11904/j.issn.1002-3070.2021.06.016

Abstract

Abstract: With the advent of the age of immunotherapy,breast cancer treatment has also opened a new treatment strategy.The application of immune checkpoint inhibitors(ICI)in the treatment of breast cancer has achieved remarkable success in clinical practice.However,because it is only effective for a small number of patients,immunotherapy may lead to the occurrence of immune-related adverse events.Therefore,the patient's treatment options must be optimized through the use of relevant biomarker.Recently,many studies have confirmed that tumor mutational burden(TMB)is an emerging biomarker that can predict the efficacy of breast cancer immunotherapy.The article reviews the predictive value and application status of TMB in immunotherapy for breast cancer patients.

Key words: Breast cancer, Tumor mutational burden, Immunotherapy, Immune checkpoint inhibitor

CLC Number:

R737.9

LI Xiang, HU Yang, ZHANG Qingyuan. Research progress of tumor mutational burden as an emerging biomarker for breast cancer immunotherapy[J]. Journal of Practical Oncology, 2021, 35(6): 568-571.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.11904/j.issn.1002-3070.2021.06.016

http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2021/V35/I6/568

References

1 国家肿瘤质控中心乳腺癌专家委员会,中国抗癌协会乳腺癌专业委员会,中国抗癌协会肿瘤药物临床研究专业委员会.中国晚期乳腺癌规范诊疗指南(2020版)[J].中华肿瘤杂志,2020,42(10):781-797.
2 Patience S,Chang X,Liu Z,et al.The recent advances of PD-1 and PD-L1 checkpoint signaling inhibition for breast cancer immunotherapy[J].Eur J Pharmacol,2021,895:173867.
3 Zachary R,Chalmers CF,Connelly DF,et al.Analysis of 100 000 human cancer genomes reveals the landscape of tumor mutational burden[J].Genome Med,2017,9(1):1-14.
4 Yarchoan M,Hopkins A,Jaffee EM.Tumor mutational burden and response rate to PD-1 inhibition[J].N Engl J Med,2017,377:2500-2501.
5 Chang L,Chang M,Chang HM,et al.Microsatellite instability:a predictive biomarker for cancer immunotherapy[J].Appl Immunohistochem Mol Morphol,2017,26(2):15-21.
6 Chabanon RM,Pedrero M,Lefebvre C,et al.Mutational landscape and sensitivity to immune checkpoint blockers[J].Clin Cancer Res,2016,22(17):4309-4321.
7 Rooney MS,Shukla SA,Wu CJ,et al.Molecular and genetic properties of tumors associated with local immune cytolytic activity[J].Cell,2015,160(1/2):48-61.
8 Cao D,Xu H,Xu X,et al.High tumor mutation burden predicts better efficacy of immunotherapy:a pooled analysis of 103078 cancer patients[J].Oncoimmunology,2019,8(9):1-12.
9 Schmid P,Adams S,Rugo HS,et al.Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer[J].N Engl J Med,2018,379(22):2108-2121.
10 Emens LA,Molinero L,Adams S,et al.Tumour mutational burden and clinical outcomes with first-line atezolizumab and nab-paclitaxel in triple-negative breast cancer:exploratory analysis of the phase III IMpassion130 trial[J].Ann Oncol,2020,31(4):360-361.
11 Karn T,Denkert C,Weber KE,et al.Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo[J].Ann Oncol,2020,31(9):1216-1222.
12 Yin Y,Li W,Huang X,et al.HER2 amplification is associated with higher tumor mutation burden in breast cancer[J].Ann Oncol,2018,29(8):146.
13 Park SE,Park K,Lee E,et al.Clinical implication of tumor mutational burden in patients with HER2-positive refractory metastatic breast cancer[J].Oncoimmunology,2018,7(8):e1466768.
14 Xu J,Bao H,Wu X,et al.Elevated tumor mutation burden and immunogenic activity in patients with hormone receptor-negative or human epidermal growth factor receptor 2-positive breast cancer[J].Oncol Lett,2019,18(1):449-455.
15 Kawaji H,Kubo M,Yamashita N,et al.Comprehensive molecular profiling broadens treatment options for breast cancer patients[J].Cancer Med,2020,10(2):529-539.
16 Barroso SR,Jain E,Cohen O,et al.Prevalence and mutational determinants of high tumor mutation burden in breast cancer[J].Ann Oncol,2020,31(3):387-394.
17 Schnidrig D,Turajlic S,Litchfield K.Tumour mutation burden:primary versus metastatic tissue creates systematic bias[J].IOTECH,2019,4:8-14.
18 Lu S,Stein JE,Rimm DL,et al.Comparison of biomarker modalities for predicting response to PD-1/PD-L1 checkpoint blockade:a systematic review and meta-analysis[J].JAMA Oncol,2019,5(8):1195-1204.
19 James JL,Balko JM.Biomarker predictors for immunotherapy benefit in breast:beyond PD-L1[J].Curr Breast Cancer Rep,2019,11(4):217-227.

[1]	LUO Bo, ZHANG Qu, ZHENG Hongmei, LIANG Xinjun, ZHOU Xiaomei, WU Xinhong. Efficacy and prognosis of SRT combined with lapatinib in the treatment of HER2-positive breast cancer brain metastasis [J]. Journal of Practical Oncology, 2021, 35(6): 523-528.
[2]	SHI Runze, LI Zhigao. Research progress of precision medical strategy for different subtypes of triple negative breast cancer [J]. Journal of Practical Oncology, 2021, 35(6): 529-533.
[3]	YANG Kaiyan, WEI Yongchang, YANG Qiuyun, TANG Fengzhu. Research progress in immunotherapy of nasopharyngeal carcinoma [J]. Journal of Practical Oncology, 2021, 35(6): 542-546.
[4]	YU Yuanyuan, MENG Qianhao, WANG Guangyu. Dilemma and future direction of gastric cancer immunotherapy [J]. Journal of Practical Oncology, 2021, 35(6): 552-556.
[5]	LIU Fei, SUI Hong. Research progress in molecular classification of liver cancer based on tumor immunological microenvironment [J]. Journal of Practical Oncology, 2021, 35(6): 557-561.
[6]	ZHOU Tianhong, GU Xiuying, YAO Fang, SONG Shuming. Analysis for screening results of breast cancer in Urumqi from 2014 to 2018 [J]. Journal of Practical Oncology, 2021, 35(5): 391-395.
[7]	ZHANG Weiming, SUN Jianping, ZHAO Yan. Co-stimulatory receptors:potential targets for tumor immunotherapy [J]. Journal of Practical Oncology, 2021, 35(5): 441-446.
[8]	MA Buhuan¹, LIU Caixia². Research progress of Jagged1 promoting the occurrence,development and distant metastasis of breast cancer [J]. Journal of Practical Oncology, 2021, 35(5): 452-457.
[9]	QIN Chao, LI Jiang, ZHENG Yadi, WANG Fei, CAO Wei, XU Yongjie, YU Yiwen, ZHAO Liang, YU Xinyang, CHEN Hongda, REN Jiansong, WANG Yong, LI Jing, LI Ni, CHEN Wanqing. Analysis of screening compliance and related factors in high-risk populations of breast cancer in Chinese cities [J]. Journal of Practical Oncology, 2021, 35(4): 291-296.
[10]	GUO Lanwei, ZHANG Shaokai, LIU Shuzheng, ZHENG Liyang, CHEN Qiong, CAO Xiaoqin, SUN Xibin, ZHANG Jiangong. Analysis of compliance with breast cancer screening and its influencing factors in urban areas of Henan province [J]. Journal of Practical Oncology, 2021, 35(4): 307-313.
[11]	MA Mingrui, LIAN Jie, LIU Chao, LOU Changjie, ZHANG Yanqiao. Exploration of “immunotherapy moving forward” for digestive system tumors [J]. Journal of Practical Oncology, 2021, 35(3): 258-262.
[12]	LI Yuying, ZHANG Yue. Research progress of Sirtuins in breast cancer [J]. Journal of Practical Oncology, 2021, 35(3): 277-281.
[13]	TI Qian, ZHANG Qingyuan. Research progress of CDK4/6 inhibitors combined with endocrine therapy for advanced breast cancer [J]. Journal of Practical Oncology, 2021, 35(3): 287-290.
[14]	YANG Min, ZHANG Jiaoyan, Duan Dan, XU Binghe. Bibliometrics and visual analysis of breast cancer caregivers [J]. Journal of Practical Oncology, 2021, 35(2): 110-116.
[15]	WANG Jianyu, ZHANG Xianyu, PANG Da. Influencing factors of neoadjuvant chemotherapy for Luminal A type breast cancer [J]. Journal of Practical Oncology, 2021, 35(2): 131-136.

Research progress of tumor mutational burden as an emerging biomarker for breast cancer immunotherapy

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments